UNSPSC 51343002: Nevirapine

This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99DK7FVK1H. European Medicines Agency schedules Nevirapine, anhydrous in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25191. Nevirapine generally arises in the molecular formula C15H14N4O. The term NEVIRAPINE is a European Pharmacopoeia designation. NEVIRAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule nevirapine under HS 29339940 and SITC 51577. As of Q4 2014, NEVIRAPINE remains the US FDA Preferred Term for this commodity. Nevirapine bears US NLM identifiers UMLS ID C0132326 and NCI Concept Code C29277. SMILES: O=C1[NH]C2C(N(C3CC3)C3NCCCC13)NCCC2C.

UNSPSC 51343002 Nevirapine is a Commodity code for a specific antiretroviral pharmaceutical product, but the recent state and local opportunities posted under this code do not reflect nevirapine procurement. Instead, the tagged solicitations cover naloxone (an opioid antagonist) and safe drug deactivation systems, which fall outside the nominal scope of the code. State and local governments use this code or related pharmaceutical UNSPSC categories to procure finished pharmaceutical products through cooperative purchasing vehicles such as MMCAP and direct competitive bidding. When pharmaceutical solicitations do align with their code designation, they typically specify unit counts, packaging configurations, shelf-life requirements, delivery schedules, and pricing on a per-unit or per-dose basis. Issuing bodies include state health departments, county health authorities, and special-purpose public health districts.

Illinois Department of Public Health and Seminole County, Florida are the two recent issuers in the available opportunities block. The Illinois procurement (posted August 28, 2026; due September 11, 2026) was a completed IFB award through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets totaling $2,999,999.11 over three contract years, not nevirapine. The Seminole County opportunity (posted June 30, 2026; due July 26, 2023—an apparent dating error in the source) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with all shipping and delivery costs included in the bid. Both opportunities required electronic submission, E-Verify compliance, and standard commercial insurance. The code shows limited recent activity aligned with its nevirapine designation, suggesting either infrequent state and local procurement of this specific pharmaceutical or systematic misclassification in notice tagging.